Navigation Links
Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
Date:9/17/2008

CRANBURY, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced that President and Chief Executive Officer John F. Crowley will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008, at 10:30 a.m. EDT in New York.

An audio webcast of the presentation will be available at the Amicus Web site at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the webcast. An audio replay of the webcast will also be available on the Company's Web site for 30 days until October 24, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Opens Research Facility in San Diego
2. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
3. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
4. Amicus Therapeutics Announces First Quarter 2008 Financial Results
5. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
7. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
10. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
11. Amicus Therapeutics to Host R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , LONDON, Sept. 8 ... services to pharmaceutical and biotechnology companies, is pleased to announce ... office. Walter Colasante, as a Vice President, and Sophie ... and reimbursement expertise and expand its current offerings. , ...
... Sept. 8 PDL BioPharma, Inc. (PDL) (Nasdaq: ... ended September 30, 2009 of approximately $71 million, as compared ... revenues are based on second quarter product sales by PDL,s ... by MedImmune. When compared with 2008, royalty revenue for foreign ...
... PAREXEL International Corporation (Nasdaq: PRXL ) announced today it ... Boston, MA. Josef von Rickenbach, Chairman and Chief Executive Officer, ... EDT on Friday, September 11, 2009. , , ... "Upcoming Events" section on PAREXEL,s "Investors" homepage at www.PAREXEL.com ...
Cached Biology Technology:PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference 2
(Date:7/9/2014)... fungal pathogens pose a greater threat to biodiversity ... of amphibians, bats, corals, bees and snakes. New ... in the prestigious journal Nature reveals ... to a deadly chytrid fungus implicated in global ... important because it is the basis of vaccination ...
(Date:7/9/2014)... from The Cancer Genome Atlas (TCGA) Research Network ... pathway in lung adenocarcinoma, the most common subtype ... may expand the number of possible therapeutic targets ... number of patients with treatable mutations because many ... exist. , TCGA is jointly funded and managed ...
(Date:7/9/2014)... be able to cope with the rising salinity of Arctic ... today is best known for its tundra and polar bear ... 38 million years ago during what is known as the ... temperate forest with brackish water, home to a variety of ... giant tortoises. Much of what is known about the region ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... of the Lawson Health Research Institute and Professor of ... of Medicine & Dentistry at The University of Western ... biology from rebro University in Sweden. Dr. ... and the only recipient this year in the field ...
... of a seething, breathing microbial world. Microorganisms populate every ... of the human skin, to rainforest floors, to hydrothermal ... powerful and pervasive role of microbes in sustaining life, ... is the subject of The Uncharted Microbial World: Microbes ...
... twins are not genetically identical. This surprising finding ... a study being published today in the prestigious journal ... be of great significance for research on hereditary diseases ... How can it be that one identical twin might ...
Cached Biology News:Unexplored microbes hold incredible potential for science and industry 2Unexplored microbes hold incredible potential for science and industry 3
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z35,347-7) or contact ...
Biology Products: